1-3 of 3
Sören Lehmann
Close
Sort by
Journal Articles

Challenging conventional karyotyping by next-generation karyotyping in 281 intensively treated patients with AML

Sylvain Mareschal, Anna Palau, Johan Lindberg, Philippe Ruminy, Christer Nilsson, Sofia Bengtzén, Marie Engvall, Anna Eriksson, Anne Neddermeyer, Vinciane Marchand, Monika Jansson, My Björklund, Fabrice Jardin, Mattias Rantalainen, Andreas Lennartsson, Lucia Cavelier, Henrik Grönberg, Sören Lehmann
Journal: Blood Advances
Blood Adv (2021) 5 (4): 1003–1016.
https://doi.org/10.1182/bloodadvances.2020002517
Published: 2021
Includes: Supplemental data
Journal Articles

Impact of treatment delay in acute myeloid leukemia revisited

Clinical Trials & Observations
Gunnar Juliusson, Oskar Hagberg, Vladimir Lj Lazarevic, Sören Lehmann, Martin Höglund
Journal: Blood Advances
Blood Adv (2021) 5 (3): 787–790.
https://doi.org/10.1182/bloodadvances.2020003806
Published: 2021
Includes: Supplemental data
Journal Articles

The prognostic impact of FLT3 -ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting

Clinical Trials & Observations
Gunnar Juliusson, Martin Jädersten, Stefan Deneberg, Sören Lehmann, Lars Möllgård, Lovisa Wennström, Petar Antunovic, Jörg Cammenga, Fryderyk Lorenz, Emma Ölander, Vladimir Lj Lazarevic, Martin Höglund
Journal: Blood Advances
Blood Adv (2020) 4 (6): 1094–1101.
https://doi.org/10.1182/bloodadvances.2019001335
Published: 2020
Includes: Supplemental data